“The Role of Alemtuzumab in the Treatment of Chronic Lymphocytic Leukemia (CLL) and the Achievement of Minimal Residual Disease Negativity in Relapsed Refractory CLL”. Hematology Meeting Reports 1, no. 2 (May 28, 2009). Accessed August 8, 2025. https://journals.pagepress.org/hmr/article/view/226.